Microbio showcases biotech innovations at 8th CIIE with three technology platforms

At the 8th China International Import Expo (CIIE) in Shanghai, Taiwan-invested Microbio Group, a company from Shanghai's Songjiang district, presented health products based on three core platforms: microbial symbiotic fermentation, exosomes, and stem cells, attracting significant interest from healthcare institutions.

Microbio Group at 8th CIIE. [Photo/WeChat ID: sh_songjiang]

In the Medical Equipment & Healthcare Products Exhibition Area, Microbio's booth was busy with inquiries from professional visitors. Many were attracted to clinical data presentations for Prime and MICRSOY series medical nutrition products.

At the 8th CIIE, a woman inquires about the details of Microbio products. [Photo/WeChat ID: sh_songjiang]

Hospital nutrition department representatives showed interest in introducing MICRSOY for patients with cancer and colitis, while health brands considered adding Microbio's Symbiota® ingredients to their gut health products.

Zhuang Hanru, deputy general manager of Microbio's Health Department, said that they are showcasing their medical-grade microbial symbiotic fermentation technology, which enables them to develop systemic health products focused on wellness and skincare. The company's products aim to support children's growth, blood sugar regulation, digestion, and skin regeneration.

Microbio products at the exhibition. [Photo/WeChat ID: sh_songjiang]

Among the highlighted products were the Prime series, including Prime Enzyme for constipation, Nurture Enzyme for children's growth, and Glyco Enzyme to help stabilize blood sugar in diabetes patients. These products utilize the Symbiota® microbial fermentation platform.

Microbio Glyco Enzyme product. [Photo/WeChat ID: sh_songjiang]

Microbio's exosome platform also uses pharmaceutical-grade purification for skin repair and anti-aging. The company plans to expand into North America, Southeast Asia, and China, pursuing global growth through brand partnerships.